Active Clinical Trials

Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.

Showing 166 results
  • Sort by Sort ascending
  • Study title
  • Condition
  • Phase
  • Location
Study title Condition Phase Location NCT ID

A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma

Follicular Lymphoma (FL) Phase3 Australia
Austria
Canada
Czechia
Hungary
Poland
Romania
Singapore
Slovakia
South Korea
Spain
Taiwan
United States
View all

Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer

Prostatic Neoplasms, Castration-Resistant Phase1 Australia
South Africa

Study of Out of Specification for Tisagenlecleucel

B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma Phase3 Japan

Kesimpta Pregnancy and Infant Safety Study Using Real World Data

Multiple Sclerosis Switzerland

Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent

Multiple Sclerosis United States

Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN

C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis Phase3 Argentina
Brazil
China
France
Germany
Greece
Israel
Italy
Japan
Netherlands
Spain
Switzerland
Turkey (Türkiye)
United Kingdom
United States
View all

Regulatory Post-Marketing Surveillance Study for Brolucizumab

Neovascular Age-related Macular Degeneration South Korea

A PMS of Jakavi® in Patients With Steroid-Refractory Graft-versus-Host Disease (SR-GvHD) in Korea

Graft-versus-Host Disease South Korea

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Phase2 France
Germany
Italy
Spain
United States
View all

Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria

Uncomplicated Plasmodium Falciparum Malaria Phase2 Burkina Faso
Côte d’Ivoire
Gabon
Ghana
Kenya
Uganda
View all